Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | LCAT | P04180 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14446187 | 0.83 | HRH3 (0.46) | HRH3KCNH2ACACBHRH1 | |
| SCHEMBL14446185 | 0.83 | HRH3 (0.44) | HRH3KCNH2ACACBLCATHRH1 | |
| SCHEMBL4698633 | 0.82 | HRH3 (0.44) | HRH3KCNH2ACACBPDE4APDE4B | |
| SCHEMBL14446209 | 0.81 | HRH3 (0.44) | HRH3KCNH2ACACB | |
| SCHEMBL14446231 | 0.81 | HRH3 (0.43) | HRH3KCNH2ACACBHRH1 | |
| SCHEMBL14446198 | 0.81 | HRH3 (0.42) | HRH3KCNH2ACACB | |
| SCHEMBL14446230 | 0.81 | HRH3 (0.43) | HRH3KCNH2ACACBHRH1 | |
| SCHEMBL14446188 | 0.80 | HRH3 (0.33) | HRH3KCNH2ACACBLCAT | |
| SCHEMBL14446199 | 0.80 | ATM (0.34) | HRH3ACACB | |
| SCHEMBL14446195 | 0.80 | ACACB (0.35) | HRH3KCNH2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711473-B1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-7241787-B2 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1711473-A1 | SUBSTITUTED N-CYCLOHEXYLIMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-08-11 | — | — | US | disclosed |
| WO-2005070898-A1 | SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176795-A1 | Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | HRH3 3058/4885KCNH2 1847/4885ACACB 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.